The National Agency for Food and Drug Administration and Control (NAFDAC), on Sunday, January 3, ruled out the possibility of conducting a local clinical trial on the proposed N400 billion vaccines before administering them on Nigerians.
According to NAFDAC, since the World Health Organization, WHO, had approved the vaccines; there might not be need to conduct another clinical trial on the vaccines.
It, however, said it would subject vaccines to proper revalidation before administering them on Nigerians.
This was disclosed by NAFDAC’s Media Consultant, Sayo Akintola, who explained that that owing to the exigencies of COVID-19; there may be no reason to conduct a trial before administering the vaccines.
“Once the vaccine arrives, a sample will be taken to the lab for a test. Once its safety and efficacy are certified by NAFDAC, it will be administered on Nigerians. We don’t expect anything to be different though.
“The truth is that once a vaccine is approved by the WHO; it is assumed that it has passed through some preliminary stage of the trial. It is a known fact that for the WHO to sanction a vaccine, it must have gone through a series of trial here and there,” he said.